User profiles for J. Mark FitzGerald
JM FitzGeraldProfessor of Medicine, University of British Columbia Verified email at vch.ca Cited by 52383 |
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
…, L Duijts, JM Drazen, JM FitzGerald… - American journal of …, 2022 - atsjournals.org
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …
updated evidence-based strategy for asthma management and prevention, which can be …
[HTML][HTML] Mepolizumab treatment in patients with severe eosinophilic asthma
…, ID Pavord, GG Brusselle, JM FitzGerald… - New England journal …, 2014 - Mass Medical Soc
Background Some patients with severe asthma have frequent exacerbations associated with
persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled …
persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled …
[HTML][HTML] Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma
…, L Ford, L Sher, JM FitzGerald… - New England journal …, 2018 - Mass Medical Soc
Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …
A summary of the new GINA strategy: a roadmap to asthma control
…, SJ Szefler, GWK Wong, JM FitzGerald - European …, 2015 - Eur Respiratory Soc
Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and
annually updated a global strategy for asthma management and prevention that has formed …
annually updated a global strategy for asthma management and prevention that has formed …
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a …
JM FitzGerald, ER Bleecker, P Nair, S Korn, K Ohta… - The Lancet, 2016 - thelancet.com
Background Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor α
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …
monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils. We …
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a …
ER Bleecker, JM FitzGerald, P Chanez, A Papi… - The Lancet, 2016 - thelancet.com
Background Eosinophilia is associated with worsening asthma severity and decreased lung
function, with increased exacerbation frequency. We assessed the safety and efficacy of …
function, with increased exacerbation frequency. We assessed the safety and efficacy of …
[HTML][HTML] Effects of an anti-TSLP antibody on allergen-induced asthmatic responses
…, D Cockcroft, J Bigler, JM FitzGerald… - … England Journal of …, 2014 - Mass Medical Soc
Background Thymic stromal lymphopoietin (TSLP) is an epithelial-cell–derived cytokine that
may be important in initiating allergic inflammation. AMG 157 is a human anti-TSLP …
may be important in initiating allergic inflammation. AMG 157 is a human anti-TSLP …
Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis
Background Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory
disorder associated with increased comorbid prevalence of cardiovascular diseases. We aimed …
disorder associated with increased comorbid prevalence of cardiovascular diseases. We aimed …
Does this dyspneic patient in the emergency department have congestive heart failure?
CS Wang, JM FitzGerald, M Schulzer, E Mak, NT Ayas - Jama, 2005 - jamanetwork.com
ContextDyspnea is a common complaint in the emergency department where physicians
must accurately make a rapid diagnosis.ObjectiveTo assess the usefulness of history, …
must accurately make a rapid diagnosis.ObjectiveTo assess the usefulness of history, …
[HTML][HTML] Inhaled combined budesonide–formoterol as needed in mild asthma
Background In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a
fast-acting β 2 -agonist may be an alternative to conventional treatment strategies. Methods …
fast-acting β 2 -agonist may be an alternative to conventional treatment strategies. Methods …